Rathbones Investment Group Lowers Stake in Advanced Medical Solutions Below 4% Reporting Threshold

Advanced Medical Solutions: Company Profile and Market Position

Advanced Medical Solutions Group PLC, registered under ISIN GB0004536594, is a UK-listed company operating in the medical device sector. It provides innovative healthcare solutions, functioning within a market influenced by regulatory demands, innovation cycles, and significant institutional investment. AMS’s strategic direction has historically attracted major UK investment managers, including substantial holdings by Rathbones.

The recent reduction in Rathbones’ stake signifies a meaningful shift in AMS’s shareholder base. Institutional investors of this magnitude typically adjust holdings based on portfolio strategies, risk evaluations, or rebalancing needs. This disclosure enhances market transparency concerning major shareholder movements, assisting other investors in assessing AMS’s outlook and institutional confidence.

Shareholding Decline: From 8.59% to 3.86% in July 2026

On 16 July 2026, Rathbones Investment Group’s combined voting rights in AMS declined to 3.861600%, down from 8.591500%. This represents a decrease of approximately 4.73 percentage points, or roughly 55% proportionally. Despite the percentage drop, Rathbones maintained a significant holding of 8,524,976 voting rights, indicating continued meaningful capital presence.

The reduction resulted from a disposal of voting rights, as indicated in the TR-1 notification. All voting rights were directly attached to shares held by Rathbones entities, with no involvement of financial instruments such as options or derivatives. This straightforward structure confirms the decrease stems from direct share disposals rather than complex financial transactions. The issuer was notified on 17 July 2026, complying with regulatory timelines.

Rathbones Group PLC’s Subsidiaries and Ownership Structure

The shareholding decrease involved three related Rathbones entities, all ultimately under Rathbones Group PLC. The disclosure details the full chain of controlled undertakings holding the voting rights, ensuring transparency of the corporate ownership structure. Rathbones Investment Management Limited, based in London, held 3.777800% of AMS voting rights post-transaction, representing the largest portion of the group’s stake.

Rathbones Investment Management International Limited, registered in St Helier, Jersey, held 0.006800%, while Rathbones Asset Management Limited, also London-based, held 0.077000%. Combined, these subsidiaries controlled 3.861600% of AMS voting rights after 16 July 2026. Such distribution across multiple entities is common among large investment managers to optimize regulatory compliance and operational efficiency.

Voting Rights and Financial Instruments Breakdown

The notification confirms all voting rights held by Rathbones entities were directly attached to shares, with no voting rights derived from financial instruments. The TR-1 form distinguishes between direct voting rights (section 8.A) and those from financial instruments (section 8.B). Rathbones’ entire 3.861600% stake corresponds to 8,524,976 shares with zero derivative exposure.

This clarity is vital for investors analyzing shareholding structures, as direct voting rights confer immediate influence in shareholder meetings and full exposure to share price movements. The absence of financial instruments indicates Rathbones’ remaining AMS stake is a core equity investment rather than a hedged or tactical position.

Regulatory Compliance and TR-1 Notification Details

The disclosure was submitted under the UK’s Disclosure and Transparency Rules (DTR) using the TR-1 form, required when voting rights cross prescribed thresholds. Rathbones’ fall below the 4% threshold triggered this mandatory notification, filed on 17 July 2026. The filing includes details of the notifying parties—Rathbones Investment Management Ltd, Rathbones Asset Management Limited, and Rathbones Investment Management International Limited—and the ultimate controlling entity, Rathbones Group PLC.

The notification was completed at the Port of Liverpool Building, Liverpool L3 1NW, providing an audit trail for regulatory compliance. Such disclosures are part of the Market Abuse Regulation (MAR) framework, ensuring timely dissemination of price-sensitive information about major shareholding changes to maintain market integrity.

Impact on Advanced Medical Solutions’ Shareholder Composition

Rathbones’ stake reduction below 4% marks a significant change in AMS’s institutional ownership landscape. Previously holding 8.59%, Rathbones was likely among the top institutional investors. The decrease to 3.86% suggests a strategic decision to reduce exposure, potentially driven by portfolio rebalancing, risk management, or capital reallocation.

This shift may alter shareholder voting dynamics and influence at general meetings. Other institutional investors might interpret Rathbones’ reduction as a signal regarding AMS’s prospects or as an opportunity to increase their holdings. Mandatory disclosure enables all market participants to evaluate these changes and their implications for AMS’s shareholder base and institutional support.

Historical Context and Threshold Crossing Mechanics

Prior to this transaction, Rathbones maintained a substantial 8.591500% holding in AMS. The crossing of the 4% threshold downward necessitates regulatory notification under UK rules, which apply to both increases and decreases in voting rights. The precise figures—8,524,976 shares representing 3.861600%—indicate a carefully managed transaction to remain just below the threshold.

Understanding threshold mechanics is important for investors, as crossing such levels triggers reporting obligations and affects market transparency. While falling below 4% reduces certain regulatory requirements, the shareholder remains publicly identifiable through RNS disclosures.

Medical Device Sector Investment Context and Institutional Behavior

Advanced Medical Solutions operates in the medical device and healthcare technology sector, which attracts strong institutional interest due to growth potential, regulatory factors, and healthcare demand. Investment managers like Rathbones regularly review portfolios to ensure alignment with fund objectives and risk profiles. The July 2026 stake reduction may reflect sector-wide considerations such as competitive pressures, regulatory developments, or company-specific factors.

Institutional ownership in healthcare is often influenced by clinical data, regulatory approvals, market access, and competition. Although the disclosure does not specify Rathbones’ rationale, investors may consider whether the reduction signals broader concerns or routine portfolio rebalancing.

Ensuring Market Transparency and Information Accessibility

The TR-1 notification serves as a critical transparency tool, ensuring all investors receive timely information on major shareholding changes. Distribution via the Regulatory News Service (RNS) guarantees simultaneous access for financial media, institutional and retail investors, supporting efficient price discovery and preventing information asymmetry.

Detailed disclosure of share numbers, voting rights percentages, dates, and ownership chains allows investors to accurately assess AMS’s shareholder structure. This transparency upholds market integrity and investor protection, providing a historical record of institutional ownership trends. The filing completion on 17 July 2026 adds this data permanently to public records, facilitating ongoing market analysis.